阳光诺和申请延期一个月回复并购重组审核问询函

Core Viewpoint - Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. has applied for a one-month extension to respond to the merger and acquisition review inquiry letter received from the Shanghai Stock Exchange [1][2] Group 1: Company Announcement - The company plans to acquire 100% equity of Jiangsu Langyan Life Science Technology Holdings Co., Ltd. through the issuance of shares and convertible bonds, while also raising matching funds from no more than 35 specific investors [1] - The company received the inquiry letter from the Shanghai Stock Exchange on November 28, 2025, regarding the asset purchase and fundraising [1] - The company has initiated a thorough review of the inquiry letter with all parties involved in the transaction and intermediary institutions to ensure the response is accurate and complete [1] Group 2: Regulatory Approval - The transaction is subject to approval from the Shanghai Stock Exchange and requires registration consent from the China Securities Regulatory Commission before implementation [2] - There is uncertainty regarding whether the transaction will pass the review and obtain the necessary regulatory approvals [2]